SeqUential GeMcitabine and MITomycin Treatment for Favorable High-Risk Upper Urinary Tract Urothelial Carcinoma

Abroad (travel likely)RecruitingPHASE2

Conditions

Urinary Bladder Cancer · Upper Tract Urothelial Cancer · Urothelial Cancer

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Rutgers Cancer Institute, New Brunswick, New Jersey, United States
Contact: Study coordinator (Vignesh Packiam, MD) · vp624@cinj.rutgers.edu · 732-235-2465

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Care of the Urothelial Cancer Patient and Prospective Procurement of Urothelial Cancer Tissue

Bladder Cancer · Urinary Tract Cancer · Urothelial Cancer

Abroad (travel likely)Recruiting

Bethesda, United States

Urinary Tumor DNA-Guided Systemic Immunotherapy for Unresectable Very-High-Risk Non-Muscle-Invasive Bladder Cancer

Bladder Cancer · Liquid Biopsy · Immunotherapy

Abroad (travel likely)RecruitingPHASE2

Tianjin, China · Tianjin, China

Dutasteride in Patients With Low Grade Non-muscle Invasive Bladder Cancer

Bladder Cancer

Abroad (travel likely)RecruitingPHASE2

Québec, Canada

Atezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients With Advanced Solid Tumors

Solid Tumor, Adult · Pancreatic Cancer · Virus-associated Tumors

Abroad (travel likely)RecruitingPHASE2

Bordeaux, France · Brest, France